Bank of America CEO Brian Moynihan’s 2025 Compensation Rises 17% to $41 Million Amid Strong Profit Growth 
Michael Kors Marks 45 Years at New York Fashion Week with Fall/Winter Collection Showcase 
Converse Cuts Corporate Jobs as Nike Restructures to Revive Sales Growth 
More U.S. Investors Join Arbitration Against South Korea Over Coupang Dispute 
Grok AI Market Share Surges as xAI Faces Scrutiny Over Image Generation Controversy 
Xiaomi EV Deliveries Surpass 600,000 Units as SU7 and YU7 Drive Strong Growth 
Anduril Industries Seeks $8 Billion Funding at $60 Billion Valuation 
Vietnam Approves SpaceX Starlink Satellite Internet Service Amid U.S. Trade Talks 
Mitsui Kinzoku Stock Surges to Record High After Profit Forecast Upgrade and Dividend Increase 
Sachem Head Boosts Warner Bros. Discovery Stake Amid Netflix Deal and Paramount Bid 
GE Aerospace Expands Singapore Engine Repair Hub with Automation and AI to Tackle Aviation Bottlenecks 
Novartis’ Vanrafia Shows Strong Phase 3 Results in IgA Nephropathy, Paving Way for Full Approval 
Valero Energy Expands Venezuelan Crude Imports as U.S. Sanctions Ease 
Paramount Skydance Appoints Rene Augustine as SVP of Global Public Policy Amid Warner Bros Takeover Battle 
Macquarie-Led Consortium to Acquire Qube Holdings in A$11.7 Billion Deal 
Vale Reports $3.8 Billion Q4 Net Loss Amid Nickel Asset Impairment and Samarco Provisions 
WALTHAM, Mass., April 26, 2018 -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that its first quarter 2018 financial results will be released on Thursday, May 3, 2018 before the U.S. financial markets open. Management will host a conference call and webcast at 8:00 a.m. ET to discuss the results and provide an update on recent corporate developments.
Dial-in Number
U.S./Canada Dial-in Number: (877) 412-6083
International Dial-in Number: (702) 495-1202
Conference ID: 6978298
Replay Dial-in Number: (855) 859-2056
Replay International Dial-in Number: (404) 537-3406
Conference ID: 6978298
A telephone replay will be available from approximately 11:00 a.m. ET on May 3, 2018 through midnight on May 9, 2018.
The webcast with slides will be accessible through the Investors section of the company’s website at www.amagpharma.com. A replay of the webcast will be archived on the website for 30 days.
About AMAG
AMAG is a biopharmaceutical company focused on developing and delivering important therapeutics, conducting clinical research in areas of unmet need and creating education and support programs for the patients and families we serve. Our currently marketed products support the health of patients in the areas of maternal and women’s health, anemia management and cancer supportive care. Through CBR®, we also help families to preserve newborn stem cells, which are used today in transplant medicine for certain cancers and blood, immune and metabolic disorders, and have the potential to play a valuable role in the ongoing development of regenerative medicine. For additional company information, please visit www.amagpharma.com.
AMAG Pharmaceuticals® is a registered trademark of AMAG Pharmaceuticals, Inc. CBR® is a registered trademark of Cbr Systems, Inc.
AMAG Pharmaceuticals Contact:
Christi Waarich
Associate Director, Investor Relations
617-498-7638
